Rule 150-14-.04 - Administration of Injectable Pharmacologics(a) For purposes of this rule, the term below shall have the following meaning. "Injectable pharmacologic" means any medication classified as a neurotoxin, adjuvant or therapeutic agent including, but not limited to, hyaluronic acid (such as Restylane), fillers (such as collagen), Botulinum Toxin Type A (such as Botox) or similar products that have been approved by the Federal Food and Drug Administration.
(b) No dentist shall administer an injectable pharmacologic unless the minimum standards of training and procedure set forth in this section are satisfied.(c) Administration of an injectable pharmacologic for the functional or cosmetic enhancement of the gums, cheeks, jaws, lips, the oral cavity and associated tissues is a procedure which can be performed by a dentist in connection with a dental procedure in a dental treatment setting.(d) A dentist may administer an injectable pharmacologic only after having completed a Board-approved post-doctoral course that is sufficient to prepare a dentist to satisfactorily administer injectable pharmacologics safely and effectively, as provided in (f) below.(e) Notwithstanding (d) above, a dentist licensed in Georgia who has successfully completed an ADA accredited oral and maxillofacial surgery advanced specialty education program shall not be required to complete the Board-approved course set forth in (f) below prior to administering injectable pharmacologics.(f) In order to obtain Board approval for a course on injectable pharmacologics, a course provider shall submit a course outline, including course content and objectives and the curriculum vitae of the instructor(s), for Board review and approval. The course outline shall indicate whether the training is visual, hands-on or lecture. An approved course shall be at least 21 hours in length and shall include advanced instruction in the following:1. Anatomy of head and neck;2. Neurophysiology, including facial tissues, parasympathetic, sympathetic and peripheral nervous systems relative to peri-oral tissue, and facial architecture;3. Patient selection, including indications and contraindications;4. Pharmacological effects and contraindications, including potential drug interactions; and5. Management of complications.(g) The course administrator shall issue a certificate of completion to a dentist who successfully completes the approved course.(h) A dentist who desires to administer injectable pharmacologics shall submit to the Board, within 30 days of completing the course, a certified true copy of the certificate of course completion provided to the dentist by the course administrator.(i) Prior to administering injectable pharmacologics to a patient, the dentist shall conduct an appropriate physical examination within the scope of dental practice, obtain a complete medical history, including the patient's medications, allergies and sensitivities and comprehensively assess the dental needs of the patient. Specific notations on the use of injectable pharmacologics, including the type of agent, dosage, duration and any untoward reactions, shall be recorded in the patient record.(j) A dentist shall not delegate the administration of an injectable pharmacologic.(k) The use of injectable pharmacologics without first having met the minimum standards for training and the procedures contained in this section shall constitute a deviation from the acceptable standards of practice required of a licensee and may subject a dentist to the penalties set forth in O.C.G.A.§ 43-11-47.Ga. Comp. R. & Regs. R. 150-14-.04
O.C.G.A. Secs. 43-1-25; 43-11-1; 43-11-7; 43-11-8; and 43-11-17.
Original Rule entitled "Administration of Injectable Pharmacologics" adopted. F. Jun. 19, 2012; eff. July 9, 2012.